Fenway Health

Running trials

• Recruiting

  A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018)

  NCT07850609· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Bridge to Belonging: Peer Led Intervention to Reduce Loneliness and Depression Among Older Gay and Bisexual Men

  NCT07762066· Fenway Community Health· Source

• Recruiting

  Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

  NCT07473778· Gilead Sciences· Source

• Recruiting

  Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

  NCT07199335· Phase 4· Massachusetts General Hospital· Source

• Active, not recruiting

  Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

  NCT07047716· Phase 3· Gilead Sciences· Source

• Recruiting

  Mitigating the Impact of Stigma and Shame Among People Living With HIV and Substance Use Disorders

  NCT05934305· Boston University· Source

• Active, not recruiting

  A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV

  NCT06812494· Phase 2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Active, not recruiting

  Transmasculine One-on-One and Group Empowerment for Targeted HIV Reduction

  NCT06182280· Fenway Community Health· Source

• Active, not recruiting

  Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

  NCT06101329· Phase 2· Gilead Sciences· Source

• Enrolling by invitation

  Alzheimer's Disease Neuroimaging Initiative 4

  NCT05617014· University of Southern California· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• HIV5 recruiting
• Alzheimer disease1 recruiting
• Frontotemporal dementia1 recruiting

Closed trials

• Completed

  Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

  NCT06045507· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Next Generation Ingestible Sensors for Medication Adherence Measurement

  NCT05592613· Phase 3· Brigham and Women's Hospital· Source

• Completed

  SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder

  NCT05378399· Phase 3· Brigham and Women's Hospital· Source

• Completed

  Life-Steps Counseling to Enhance Adherence and Engagement in PrEP Care

  NCT04316715· University of Miami· Source

• Completed

  Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)

  NCT03512418· Phase 3· Brigham and Women's Hospital· Source

• Completed

  Integrated BA and HIV RR Counseling for MSM With Stimulant Abuse

  NCT03175159· University of California, Los Angeles· Source

• Completed

  A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

  NCT02935686· Phase 1/2· Janssen Vaccines & Prevention B.V.· Source

• Completed

  Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

  NCT02720094· Phase 2/3· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

  NCT02135419· Phase 3· AIDS Malignancy Consortium· Source

Conditions

Diseases this institution publishes on or runs trials for.

• HIV64 works · 18 trials